Seagen (SGEN)

167.62 -5.79 (3.34%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/8/21 *Est.)
- M&A (3/31/18 *Est)

Latest Headlines

Form 4 Seagen Inc. For: Nov 05 Filed by: SIMPSON TODD E November 9, 2020 7:26 PM - SEC Filing Seagen Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtual Annual Meeting 2020 November 9, 2020 8:00 AM - BizWire Form 4 Seagen Inc. For: Nov 05 Filed by: GRYSKA DAVID W November 6, 2020 7:54 PM - SEC Filing Form 4 Seagen Inc. For: Nov 04 Filed by: ROMP CHARLES R November 6, 2020 7:35 PM - SEC Filing Form 4 Seagen Inc. For: Nov 04 Filed by: DANSEY ROGER D November 5, 2020 9:38 PM - SEC Filing Form 4 Seagen Inc. For: Nov 03 Filed by: LIPPMAN MARC E November 5, 2020 8:45 PM - SEC Filing Seagen Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Upcoming ASH Annual Meeting November 5, 2020 8:00 AM - BizWire Form 4 Seagen Inc. For: Nov 02 Filed by: WELCH DANIEL G November 4, 2020 8:52 PM - SEC Filing Form 4 Seagen Inc. For: Nov 02 Filed by: ROMP CHARLES R November 4, 2020 8:23 PM - SEC Filing Seagen to Host Virtual R&D Day on November 16, 2020 November 2, 2020 8:00 AM - BizWire Seagen (SGEN) PT Lowered to $188 at RBC Capital October 30, 2020 6:23 AM - StreetInsider Form 10-Q Seagen Inc. For: Sep 30 October 30, 2020 6:19 AM - SEC Filing Seagen (SGEN) PT Raised to $177 at Barclays October 30, 2020 5:09 AM - StreetInsider Form 8-K Seagen Inc. For: Oct 29 October 29, 2020 4:09 PM - SEC Filing Seagen (SGEN) Tops Q3 EPS by $3.00, Revenues Beat October 29, 2020 4:06 PM - StreetInsider Seagen Reports Third Quarter 2020 Financial Results October 29, 2020 4:02 PM - BizWire Seagen Announces Closing of $1.0 Billion Stock Sale to Merck October 28, 2020 8:00 AM - BizWire Merck Announces Third-Quarter 2020 Financial Results October 27, 2020 6:45 AM - BizWire Form 8-K Seagen Inc. For: Oct 19 October 20, 2020 6:05 AM - SEC Filing Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2020 Financial Results on October 29, 2020 October 13, 2020 8:00 AM - BizWire Form 8-K Seagen Inc. For: Oct 12 October 13, 2020 7:32 AM - SEC Filing Seagen (SGEN) PT Raised to $216 at JMP Securities October 13, 2020 4:17 AM - StreetInsider Seagen (SGEN) and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV in Advanced UC October 12, 2020 6:46 AM - StreetInsider Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer October 12, 2020 6:45 AM - BizWire Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer October 12, 2020 6:45 AM - PR NewsWire Form 8-K SEATTLE GENETICS INC For: Oct 06 October 8, 2020 8:29 AM - SEC Filing Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc. October 8, 2020 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Sep 21 Filed by: LIU JEAN I September 23, 2020 7:29 PM - SEC Filing Seattle Genetics (SGEN) PT Raised to $165 at Stifel After Considering Merck Contribution September 22, 2020 6:44 AM - StreetInsider Seattle Genetics (SGEN) PT Raised to $200 at JMP Securities After Positive ESMO Data and Commentary September 22, 2020 6:31 AM - StreetInsider Seattle Genetics (SGEN) PT Raised to $187 at SVB Leerink September 22, 2020 6:17 AM - StreetInsider Seattle Genetics (SGEN) and Genmab (GMAB) Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO September 21, 2020 10:20 AM - StreetInsider Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020 September 21, 2020 10:20 AM - BizWire Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020 September 21, 2020 10:20 AM - StreetInsider Form 8-K SEATTLE GENETICS INC For: Sep 18 September 18, 2020 6:59 AM - SEC Filing Seattle Genetics (SGEN), Astellas Report PADCEV (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial September 18, 2020 6:46 AM - StreetInsider Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cance September 18, 2020 6:45 AM - PR NewsWire Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cance September 18, 2020 6:45 AM - BizWire Form 4 SEATTLE GENETICS INC For: Sep 14 Filed by: LIU JEAN I September 16, 2020 6:53 PM - SEC Filing Seattle Genetics (SGEN) PT Raised to $185 at SVB Leerink September 15, 2020 6:26 AM - StreetInsider Seattle Genetics (SGEN) PT Raised to $187 at Guggenheim September 14, 2020 2:59 PM - StreetInsider Seattle Genetics (SGEN) PT Raised to $191 at RBC Capital September 14, 2020 1:59 PM - StreetInsider Seattle Genetics (SGEN) PT Raised to $175 at Cowen September 14, 2020 12:25 PM - StreetInsider Merck (MRK), Seattle Genetics (SGEN) announce new collaborations and investment, analysts see positives in them September 14, 2020 10:22 AM - StreetInsider Pre-Open Stock Movers 09/14: (IMMU) (SGMS) (NVDA) Higher; (GILD) (MGM) (WMT) Lower (more...) September 14, 2020 9:30 AM - StreetInsider Options expected to have increasing volume: SGEN MRK UBS CS DB September 14, 2020 8:59 AM - StreetInsider Seattle Genetics (SGEN) option implied volatility at 46 into Merck (MRK) to acquire $1B equity stake September 14, 2020 8:55 AM - StreetInsider Form 8-K SEATTLE GENETICS INC For: Sep 12 September 14, 2020 6:57 AM - SEC Filing Seattle Genetics (SGEN) and Merck (MRK) Announce Two Strategic Oncology Collaborations; Merck to Invest $1B September 14, 2020 6:45 AM - StreetInsider Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations September 14, 2020 6:45 AM - BizWire Form 4 SEATTLE GENETICS INC For: Sep 09 Filed by: HIMES VAUGHN B September 11, 2020 6:26 PM - SEC Filing Seattle Genetics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference September 3, 2020 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Aug 31 Filed by: DANSEY ROGER D September 2, 2020 7:26 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 31 Filed by: HIMES VAUGHN B September 2, 2020 7:25 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 31 Filed by: LIU JEAN I September 2, 2020 7:25 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 31 Filed by: ROMP CHARLES R September 2, 2020 7:25 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 31 Filed by: SIMPSON TODD E September 2, 2020 7:25 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Aug 31 Filed by: SIEGALL CLAY B September 2, 2020 7:25 PM - SEC Filing Seattle Genetics (SGEN) to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline (GSK) Following EC Approval of BLENREP August 27, 2020 8:11 AM - StreetInsider Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP (belantamab mafodotin) August 27, 2020 8:10 AM - BizWire Seattle Genetics Highlights Data from Broad Oncology Portfolio During ESMO Virtual Congress 2020 August 27, 2020 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Aug 21 Filed by: SIEGALL CLAY B August 25, 2020 6:35 PM - SEC Filing Full Article List